- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
IGFBP3 Antibody (C-term)Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP7641b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
IGFBP3 Antibody (C-term) - Product info | |
| Application | IHC
|
| Primary Accession | P17936 |
| Other Accession | P15473 |
| Reactivity | Human |
| Predicted | Rat |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 31674 Da |
IGFBP3 Antibody (C-term) - Additional info | |
| Gene ID 3486 | |
| Other Names IGFBP3; IBP3; Insulin-like growth factor-binding protein 3 | |
| Target/Specificity This IGFBP3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 262~291 amino acids from the C-terminal region of human IGFBP3. | |
| Dilution IHC~~1:10~50 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions IGFBP3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
IGFBP3 Antibody (C-term) - Protein Information | |
| Name IGFBP3 | |
| Synonyms IBP3 | |
| Function IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R | |
| Cellular Location Secreted. | |
| Tissue Location Expressed by most tissues. Present in plasma. | |
IGFBP3 Antibody (C-term) - Related products
AP3684a: Phospho-IGFBP-3-pS183 Antibody
AP7641a: IGFBP3 Antibody (N-term)
AP7641b: IGFBP3 Antibody (C-term)
AP7641d: IGFBP3 Antibody (S183)
RI12662: IGFBP3 predesign siRNA
BP3684a: Phospho-IGFBP-3-pS183 Antibody Blocking Peptide
BP7641a: IGFBP3 Antibody (N-term) Blocking Peptide
IGFBP3 Antibody (C-term) - Application data
-
Formalin-fixed and paraffin-embedded human hepatocarcinoma tissue reacted with IGFBP3 Antibody (C-term)(Cat.#AP7641b), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
IGFBP3 Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
IGFBP3 is a member of the insulin-like growth factor binding protein (IGFBP) family with an IGFBP domain and a thyroglobulin type-I domain. This protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.
REFERENCES
Muzumdar,R.H., Diabetes 55 (10), 2788-2796 (2006) Novosyadlyy,R., Growth Horm. IGF Res. 15 (5), 313-323 (2005)